FDA
-
-
-
-
-
-
-
Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
-
-
-
-
-
-
-
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025
-
-
-
-
-
-
-
Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch
-
-
-
-
-
-
-
New Data for Genentech’s Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD)
-
-
-
-
-
-
-
Roche's (RHHBY) Genentech presents results from Phase 3 study of Lunsumio
-
-
-
-
-
-
-
FDA Approves Genentech’s Susvimo for Diabetic Retinopathy
-
-
-
-
-
-
-
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

